Affimed N.V. announced the appointment of Dr. Leila Alland to the position of Chief Medical Officer (CMO), effective March 26, 2018. As CMO, Dr. Alland will be responsible for the clinical strategy and execution of the company's first-in-class NK and T cell engager programs through early and late stage clinical trials. Dr. Alland brings to the company over 20 years of experience in industry and academic research with a strong track record of successful oncology and hematology drug development.